文献速递炎症性肠病

维生素D补充对炎症性肠病临床结局的真实世界影响

The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-22

该回顾性队列研究纳入2000至2023年美国退伍军人健康管理局系统中5021例炎症性肠病患者,采用双重差分分析比较补充与未补充维生素D组在25-羟基维生素D检测前后的结局。补充维生素D与炎症性肠病相关急诊就诊减少2.17%、住院减少2.64%、皮质类固醇处方减少1.29%相关。

要点

  • 补充维生素D与炎症性肠病相关急诊就诊减少2.17%相关(相对风险降低34.4%,P=0.007)。
  • 补充维生素D与炎症性肠病相关住院减少2.64%相关(相对风险降低53.18%,P=0.003)。
  • 补充维生素D与皮质类固醇处方减少1.29%相关(相对风险降低25.13%,P=0.066)。

核心结论

  • 补充维生素D与炎症性肠病相关急诊就诊、住院和皮质类固醇使用减少相关,支持其作为炎症性肠病管理中低成本辅助手段的潜力。
  • 需要前瞻性研究来优化给药策略并确定改善长期结局的目标血清水平。

研究设计与样本

  • 回顾性队列研究,纳入2000至2023年美国退伍军人健康管理局系统中5021例炎症性肠病患者。
  • 纳入在既往3个月内无维生素D处方且进行维生素D实验室检测的所有患者。
  • 采用准实验设计中的双重差分分析,比较维生素D治疗组与未治疗组在25-羟基维生素D检测前后的结局。
  • 敏感性分析使用回归间断设计和逆概率加权回归以确认主要分析结果。

主要发现

  • 5021例炎症性肠病患者中位年龄63岁,89%为男性,58%为溃疡性结肠炎,39%为克罗恩病,3%为未定型结肠炎。
  • 中位25-羟基维生素D水平为23 ng/mL,41%接受维生素D补充。
  • 补充维生素D与炎症性肠病相关急诊就诊减少2.17%相关(相对风险降低34.4%,P=0.007)。
  • 补充维生素D与炎症性肠病相关住院减少2.64%相关(相对风险降低53.18%,P=0.003)。
  • 补充维生素D与皮质类固醇处方减少1.29%相关(相对风险降低25.13%,P=0.066)。

临床怎么用

  • 作者认为补充维生素D与炎症性肠病相关急诊就诊、住院和皮质类固醇使用减少相关,支持其作为炎症性肠病管理中低成本辅助手段的潜力。
  • 作者指出需要前瞻性研究来优化给药策略并确定改善长期结局的目标血清水平。

局限性

  • 需要前瞻性研究来优化给药策略并确定改善长期结局的目标血清水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Vitamin D deficiency is common in inflammatory bowel disease (IBD) and linked to adverse outcomes, yet the therapeutic role of vitamin D supplementation remains uncertain. We evaluated the real-world impact of vitamin D supplementation on corticosteroid use, emergency department visits, and hospitalizations in patients with IBD. METHODS: We conducted a retrospective cohort study of patients with IBD seen in the national Veterans Health Administration system from 2000 to 2023. All patients who had a vitamin D laboratory assay without a vitamin D prescription in the preceding 3 months were included. We used the quasi-experimental design with difference-in-differences analysis to compare vitamin D-treated and untreated groups before and after the 25-hydroxyvitamin D assay. Sensitivity analyses used regression discontinuity design and inverse probability weighting regression to confirm results from the primary analysis. RESULTS: Among 5021 patients with IBD (median age, 63; 89% male; 58% ulcerative colitis, 39% Crohn's disease, 3% indeterminate colitis), the median 25-hydroxyvitamin D level was 23 ng/mL, and 41% received vitamin D supplementation. Vitamin D supplementation was associated with reduction in IBD-related emergency department visits by 2.17% (34.4% relative risk reduction; P = .007), hospitalizations by 2.64% (53.18% relative risk reduction; P = .003), and corticosteroid prescriptions by 1.29% (25.13% relative risk reduction; P = .066). Similar results were seen in the inverse probability weighted regression and regression discontinuity design analyses. CONCLUSIONS: Vitamin D supplementation was associated with reduced IBD-related emergency department visits, hospitalizations, and corticosteroid use, supporting its potential as a low-cost adjunct in IBD management. Prospective studies are needed to optimize dosing strategies and define target serum levels for improved long-term outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sninsky JA, Sansgiry S, Taylor T, et al. The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes. Clin Gastroenterol Hepatol. 2025. PMID: 40706735. doi:10.1016/j.cgh.2025.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。